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To determine whether HIV-1 infection and HIV-1–relat-
ed immunosuppression were risk factors for severe malaria 
in adults with some immunity to malaria, we conducted a 
case–control study in Luanshya, Zambia, during Decem-
ber 2005–March 2007. For each case-patient with severe 
malaria, we selected 2 matched controls (an adult with un-
complicated malaria and an adult without signs of disease). 
HIV-1 infection was present in 93% of case-patients, in 
52% of controls with uncomplicated malaria, and in 45% of 
asymptomatic controls. HIV-1 infection was a highly sig-
niﬁ  cant risk factor for adults with severe malaria compared 
with controls with uncomplicated malaria (odds ratio [OR] 
12.6, 95% conﬁ  dence interval [CI] 2.0–78.8, p = 0.0005) 
and asymptomatic controls (OR 16.6, 95% CI 2.5–111.5, p 
= 0.0005). Persons with severe malaria were more likely to 
have a CD4 count <350/μL than were asymptomatic con-
trols (OR 23.0, 95% CI 3.35–158.00, p<0.0001).
T
he geographic overlap between HIV-1 infection and 
malaria, particularly in eastern and southern Africa, 
has caused concern since the 1980s. The degree of inter-
action between HIV-1 infection and malaria emerged dur-
ing 1999–2009 and has been extensively reviewed for both 
nonpregnant and pregnant adult women (1,2). The effect of 
HIV-1 on malaria seems to be driven mainly by the incapac-
ity of the immune system to control parasite load, leading 
to a higher prevalence of infection (3), a higher incidence 
of clinical malaria (4,5), and a risk for treatment failure (6) 
in immunosuppressed HIV-1 patients.
Reports of HIV-1 infection as a risk factor for hyper-
parasitemia or severe malaria are few and limited. In urban 
Burkina Faso, >30% of adults with severe malaria were 
also infected with HIV-1, whereas HIV-1 prevalence in the 
general adult population was ≈5%–14% (7). In South Af-
rica, in an area of low malaria transmission (<1 case/1000/
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year), HIV-1 infection was associated with severe falci-
parum malaria (8–10). Similarly, in Mumbai, India, where 
malaria transmission is low, HIV-1 prevalence was higher 
in persons with severe malaria than in the general popula-
tion (11). Therefore, in areas of low malaria transmission, 
HIV-1 infection seems to be an important risk factor for 
severe malaria and death. In areas of high malaria transmis-
sion (>1/case/1000/year), the relationship between HIV-1 
infection and severe malaria is less well established, with 
a small hospital-based study in Zimbabwe reporting higher 
risk for severe malaria and related death in HIV-1–infected 
adults than in HIV-1–uninfected adults (12). In all these 
studies, either the number of cases was small or HIV-1 test-
ing was not performed, and CD4 cell count was not rou-
tinely done. The effect of both HIV-1 infection and malaria 
is important in several African countries with high malaria 
endemicity. We report the results of a matched case–control 
study exploring whether HIV-1 is an important risk factor 
for severe malaria in adults living Luanshya, Zambia, an 
area of high malaria transmission (>200/cases/year).
Methods
Study Design
We chose a case–control design for this study because 
severe malaria is relatively rare in areas of stable transmis-
sion (13). Each adult with severe malaria was matched 
with 2 controls: 1 adult who had uncomplicated malaria 
and 1 asymptomatic adult in the community. We matched 
for major confounding variables: age group (15–19, 20–29, 
30–39, and 40–49 years), sex, area of residence, and sea-
sonal variation. Controls were recruited within 4 weeks af-
ter identiﬁ  cation of case-patients.
Study Site and Patients
The study was conducted at Thompson Hospital, a 
government district hospital serving Luanshya district in 
the Copperbelt province of Zambia. In this district, 99% of 
the population is at risk for malaria (Figure), and 30% of 
women attending voluntary counseling and testing at the 
antenatal care department are infected with HIV-1 (15). 
Luanshya is not a site of sentinel surveillance for HIV, but 
sentinel surveillance conducted during late 2004 and early 
2005 in the adjacent district of Ndola showed an HIV prev-
alence rate of 30% (16). From October 2005 through April 
2007, all patients 15–49 years of age who sought treatment 
for symptoms and signs of febrile illness were screened for 
falciparum malaria by thick and thin blood smear. Patients 
in whom severe malaria was diagnosed were enrolled after 
informed consent was given by the patient or by his or her 
legally authorized representative. We deﬁ  ned severe ma-
laria (16) as fever (body temperature >37.5°C ) or history 
of fever in the previous 48 hours, Plasmodium falciparum 
monoinfection with a density of at least 100 parasites per 
200 leukocytes (assumed to be >4,000 parasites/μL) in the 
absence of any other evident causes of illness, and at least 
1 of the following signs: impaired consciousness (Glasgow 
Coma Score <10), multiple grand mal convulsions, jaun-
dice, hypoglycemia (glycemia <2.5 mmol/L), hyperpara-
sitemia (parasite density >100,000/μL), renal impairment, 
and cardiorespiratory distress. We collected information 
about anemia but did not include anemia in the case deﬁ  ni-
tion because it can be HIV-1 related, resulting in possible 
bias, and because uncomplicated and severe malaria epi-
sodes can be misclassiﬁ  ed in HIV-1–infected persons.
Patients with severe malaria were treated according to 
the national guidelines for severe malaria in Zambia (i.e., 
quinine 10 mg/kg/8 h for 7 d), with adequate supportive 
treatment (17). On the basis of information about areas of 
unstable malaria and of HIV surveillance data in Zambia, we 
predicted that HIV-1 increased the risk for severe malaria 
5-fold and assumed a 30% HIV-1 prevalence (primary ex-
posure) among controls. Using a 1:1 case:control ratio, we 
determined that we needed to recruit 30 case–control pairs 
to detect this risk with 80% power. Recruitment of cases 
continued until the required sample size was reached.
Controls with uncomplicated malaria were selected 
from the clinic closest to the homes of the case-patients. The 
ﬁ  rst patient attending the clinic and exhibiting fever or hav-
ing a history of fever in the previous 48 hours, without any 
other disease, with a positive rapid diagnostic test, residing 
in the catchment area of the health center, matching sex and 
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Figure. Malaria endemicity in Zambia. This map is a product of 
the Mapping Malaria Risk in Africa/Atlas du Risque de la Malaria 
en Afrique (MARA/ARMA) collaboration (www.mara.org.za), July 
2005. Malaria distribution was obtained from Craig et al. (14). 
Topographic data were obtained from African Data Sampler, World 
Resources Institute (www.igc.org/wri/sdis/maps/ads/ads_idx.htm).HIV-1 and Severe Malaria
age group of the case-patient, and willing to participate was 
recruited as a control. Pregnant women were excluded.
Field trips were organized to case-patients’ residences, 
where, following the random sampling method, a com-
munity control was identiﬁ  ed and independently assessed. 
The ﬁ  rst healthy asymptomatic adult fulﬁ  lling the matching 
criteria and willing to participate was recruited as a com-
munity control. Pregnant women were excluded. All com-
munity controls were assessed for possible confounding 
factors and screened for falciparum malaria by thick and 
thin blood smear. We sought to identify controls within 4 
weeks after we recruited a case-patient.
Laboratory Tests
Laboratory technicians were blinded to patient identity 
and to patient-related parameters. We used microscopy to 
screen case-patients and community controls for malaria 
using Giemsa staining 10% for 5 min. A thin blood ﬁ  lm 
was examined to identify type of parasite; a thick ﬁ  lm was 
taken for quantiﬁ  cation. Computation of parasite density 
took into consideration the actual leukocyte count. In as-
ymptomatic controls, we screened for P. falciparum infec-
tion by using a rapid diagnostic test, Malaria Pf immuno-
chromatographic test (ICT) (ICT Diagnostics, Cape Town, 
South Africa). For each participant, a blood sample (0.5 
mL) was collected for HIV-1 testing and CD4 cell count, 
and for hemoglobin (1 mL), by venipuncture. Neither the 
study staff nor the patient had access to the HIV-1 test 
results. HIV-1 testing followed an unlinked anonymous 
procedure: blood samples were sent to the hospital labora-
tory, where they were processed anonymously. Determine 
HIV1/2/O (Abbott Laboratories, Abbott Park, IL, USA) 
was the ﬁ  rst test. If test results were negative, the patient 
was considered not infected. If results were positive or in-
determinate, the blood sample was tested with Unigold Re-
combinant HIV-1/2 (Trinity Biotech PLC, Bray, Ireland); 
if results were positive, the patient was classiﬁ  ed as HIV-1 
infected. If results were negative, the outcome was consid-
ered indeterminate, and the sample was further tested with 
ELISA and Western blot. Patients, after recovering from 
malaria, and controls were counseled about HIV-1 and of-
fered the opportunity for voluntary counseling and testing.
CD4 counts were determined by ﬂ  ow cytometry on a 
CyFlow (Cyﬂ  ow Counter, Partec, Germany) within 5 hours 
after collection, and multiset software was used to obtain 
the absolute counts and the CD4+ lymphocyte ratio (18). 
A FACSCount machine (Becton Dickinson, Sparks, MD, 
USA) was used as a quality control to validate the accuracy 
of the Cyﬂ  ow data over time and served as backup.
Ethics and Consent
The trial was approved by the ethical committee of 
the Institute of Tropical Medicine, Antwerp, Belgium, and 
by the Research Ethics Committee of the Tropical Disease 
Research Centre, Ndola, Zambia. The written informed 
consent signed by study participants or their legally autho-
rized representatives described the purpose of the study, 
procedures followed, and risks and beneﬁ  ts of participa-
tion. The consent form was in both English and the local 
language. Patients were counseled on HIV and offered the 
opportunity to undergo voluntary counseling and testing in 
conjunction with the study; this procedure was followed to 
ensure adherence to the standard of counseling and test-
ing stipulated in the guidelines for HIV/AIDS counseling 
in Zambia (17).
Statistical Analysis
Crude associations between the primary outcome mea-
sures and potential risk factors, including HIV-1 status and 
HIV-1–related immunosuppression (HIV-1+ with CD4 
>350/μL and HIV-1+ with CD4 <350/μL), were described 
by using summary statistics, means, and count and were 
tested by using Wilcoxon signed rank test for matched vari-
ables.
Results
From December 2005 through March 2007, we re-
cruited 30 case-patients with severe malaria, 30 controls 
with uncomplicated malaria, and 30 asymptomatic com-
munity controls who fulﬁ  lled all inclusion criteria. Because 
of the low malaria incidence among adults, 5 controls with 
uncomplicated malaria who met the matching criteria could 
not be identiﬁ  ed within 28 days after admission of the case-
patient to the hospital. One case-patient and corresponding 
matched controls were omitted because of missing labora-
tory results. One case-patient was recruited during March–
October 2006, the low malaria transmission season. Me-
dian age was 33 years, and men and women were equally 
represented (Table 1). Eighty-six percent of participants 
lived in concrete houses. Households contained an average 
of 4.7 inhabitants, few of whom slept under a bed net (1.5 
persons per household, 32%). Only 24% of case-patients 
(7/29) had slept under a bed net before admission.
Impaired consciousness and hypoglycemia were the 
most common signs of severe malaria in HIV-1–infected 
case-patients (Table 2). Nineteen percent of patients, all 
HIV-1 infected, had anemia. All parasite densities were 
above the fever threshold (2,088/μL–635,500/μL), conser-
vatively set at 2,000 parasites/μL. Seven of 13 patients with 
a parasite density below the geometric mean were treated 
with quinine only; others conservatively received some 
antimicrobial drugs. Six case-patients, all HIV-1–infected, 
had hyperparasitemia, 5 with >200,000 parasites/μL. None 
of the case-patients were receiving antiretroviral drugs or 
cotrimoxazole prophylaxis. Fifteen case-patients received 
concomitant antimicrobial drug treatment(s) determined 
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by clinical symptoms: penicillin (8 patients), amoxicillin 
(1), gentamicin (2), metronidazole (1), ﬂ  uconazole  (2), 
chloramphenicol (3), ciproﬂ  oxacin (1), and cotrimoxazole 
(4). Clinical history, symptoms, outcome, illness duration, 
and other relevant parameters were similar in case-patients 
who received concomitant antmicrobial drugs and in those 
who received quinine only. Five (19%) patients died, 4 
within 2 days after admission. Median length of hospital 
stay for successfully treated patients was 5.5 days. Case-
patients were more likely to have used antimalarial treat-
ment (45%) during the week before admission than were 
controls with uncomplicated malaria (28%) and asymp-
tomatic controls (17%) (Table 1). Three case-patients used 
antimicrobial agents the week before admission, compared 
with 2 controls with uncomplicated malaria and 1 asymp-
tomatic control.
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Table 1. Risk factors for severe malaria in case–control study, Luanshya, Zambia 
Risk factors 
Case-patients,
n = 29 
Controls with uncomplicated 
malaria, n = 29 
Asymptomatic 
controls, n = 29  p value 
Demographic characteristics* 
  GM† age, y (range)  33 (18–50)  33 (20–49)  33 (18–50) 
  No. (%) male  14 (48)  14 (48)  14 (48) 
Living conditions† 
  No. (%) living in mud/clay hut  4 (14)  4 (14)  5 (17)  0.91
  No. (%) living in concrete house  25 (86)  25 (86)  24 (83) 
  GM no. persons living in house* (95% CI)  4.7 (3.7–6.0)  3.6 (2.9–4.5)  4.7 (3.8–5.8)  0.76
  Mean no. sleeping under bed net (95% CI)  1.5 (0.7–2.3)  1.5 (0.7–2.3)  1.4 (0.5–2.3)  0.85
  No. (%) sleeping under bed net  7 (24)  9 (31)  9 (31)  0.80
No. (%) using antimalarial drug during previous week  13 (45)  8 (28)  5 (17)  0.13
  No. using quinine  2 2 1
  No. using sulfadoxine pyrimethamine  8 5 3
  No. using artemether–lumefantrine  5 1 0
No. (%) with HIV-1  27 (93)  15 (52)  13 (45)  0.03
  GM CD4 count (95% CI)‡  173 (125–240)  205 (112–377)  677 (427–1074) 
  No. (%) CD4 count <200/μL‡  11/23 (48)  5/14 (36)  1/12 (8)  <0.001
  No. (%) CD4 count <350/μL‡  19/23 (83)  11/14 (79)  1/12 (8)  <0.001
*Matching variables. 
†GM, geometric mean; CI, confidence interval. 
‡Not measured in 4 case-patients, 1 control with uncomplicated malaria, and 1 asymptomatic control because of technical constraints. 
Table 2. Clinical features of case-patients with severe malaria in case–control study, by HIV-1 infection status, Luanshya, Zambia
Clinical features  HIV-1 infected, n = 27  HIV-1 uninfected,* n = 2 
Signs and symptoms, no. (%) 
  Fever (>37.5°C)  20 (74)  1 (50) 
  History of fever  25 (93)  2 (100) 
  Impaired consciousness (Glasgow Coma Score <10)  15 (56)  0 (0) 
  Severe anemia (<7 g/dL)†  5 (19)  0 (0) 
  Convulsions  6 (22)  0 (0) 
 Jaundice  3 (11)  1 (50) 
  Hypoglycemia (<2.5 mmol/L)  11 (41)  0 (0) 
 Hyperparasitemia  (>100,000  parasites/μL)  6 (22)  0 (0) 
  Renal impairment  0 (0.0)  0 (0) 
Leukocyte count, mean 1,000/μL (SD)‡  6.9 (3.9)  4.2 and 8.7 
  Lymphocytes, % (SD)‡  25 (11)  18
 Monocytes,  %  (SD)‡ 11  (6)  5.2
 Granulocytes,  %  (SD)‡ 62  (20)  76.8
Parasite density, geometric mean/UL (95% confidence interval)  43,314 (25,467–81,145)  11,745 and 38,942 
Concomitant antimicrobial drugs  15 (56)  0
Outcome
  No. (%) discharged  24 (82)  2 (100) 
    Median time hospitalized, d (range)  5.5 (1–31)  4 and 17 
  No. deceased (case-fatality ratio)  5 (19)  0
    Median length of illness before death, d (range)  2 (1–11)  –
*Because only 2 results were HIV negative, no SD or confidence interval was specified. 
†Anemia was not an inclusion criterion. 
‡Not measured in 4 patients because of technical constraints. HIV-1 and Severe Malaria
Risk Analysis
Case-patients differed from controls in use of other 
drugs during the previous week, HIV-1 infection, and CD4 
count. No parasitemia was detected in any asymptomatic 
controls. Because of the matching, controls with uncom-
plicated malaria and asymptomatic controls were similar to 
case-patients for all other assessed risk factors (Table 1).
HIV-1 infection was detected in 45% of asymptomat-
ic controls, 52% of controls with uncomplicated malaria, 
and 93% of case-patients. HIV-1 infection was not a risk 
factor for uncomplicated malaria (odds ratio [OR] 1.3, 
95% conﬁ  dence interval [CI] 0.5–3.7, p = 0.59) (Table 
3). Case-patients were more likely to be infected with 
HIV-1 than were controls with uncomplicated malaria 
and asymptomatic controls (OR 12.6, 95% CI 2.0–78.8, 
p = 0.0005, and OR 16.6, 95% CI 2.5–111.8, p = 0.0005, 
respectively).
Eighty-three percent of case-patients had a CD4 count 
<350/μL, compared with 79% of controls with uncompli-
cated malaria (p = 0.76) and 8% of asymptomatic controls 
(p<0.0001). Controls with uncomplicated malaria were 
more likely than asymptomatic controls to have a CD4 
count <350/μL (OR 7.67, 95% CI 1.78–33.01, p = 0.001). 
Case-patients were more likely to have a CD4 count <350/
μL than were asymptomatic controls (OR 23.00, 95% CI 
3.35–158.00, p<0.0001) but not controls with uncompli-
cated malaria (OR 3.00, 95% CI 0.83–10.83, p = 0.32).
The extremely high proportion of low CD4 count in 
both case-patients and controls with uncomplicated malaria 
might be confounded by a temporary malaria-induced real-
location of speciﬁ  c T-cells (19). Therefore, 28 days after 
successful treatment, the absolute CD4 count was measured 
in 10 HIV-infected case-patients. During this period, the 
mean CD4 count increased >2-fold, from 142 (95% CI 76–
269) to 320 CD4/μL (95% CI 169–607) (data not shown). 
However, the proportion of case-patients with CD4 count 
<350/μL remained substantial (70%), although slightly less 
than at admission (90%).
Discussion
In Luanshya, Zambia, an area where malaria is me-
soendemic, HIV-1 infection is an important risk factor 
for severe malaria in adults, primarily in those with a low 
CD4 count. The increased risk for severe malaria in HIV-
1–infected persons already has been reported from areas 
of low and unstable transmission (8–11) but never has 
been ﬁ  rmly established in areas of stable malaria trans-
mission. The paucity of information results from the difﬁ  -
culty of obtaining it. Studies collecting relevant informa-
tion retrospectively are vulnerable to considerable bias, 
and prospective studies are difﬁ  cult to carry out where 
adults have acquired immunity and severe malaria is rare 
(20). In our study, recruitment of 30 persons with severe 
malaria from a population of 10,000 persons took 2 years. 
However, even prospectively, diagnosing severe malaria 
with certainty might be difﬁ  cult, particularly in the pres-
ence of HIV-1 co-infection, because several opportunistic 
infections of AIDS patients could have clinical presenta-
tions similar to those of severe malaria. Persons with se-
vere malaria could have had a concomitant Streptococcus 
pneumoniae or Salmonella enterica serovar Typhimurium 
infection (21) or HIV-1 immunosuppression-related men-
ingitis, such as cryptococcal meningitis. Although, none 
of the case-patients we recruited were identiﬁ  ed by the 
treating physicians as having clinical AIDS, in the ab-
sence of a blood culture, physicians conservatively de-
cided to concomitantly prescribe antimicrobial drugs in 
15 cases. More detailed review of patients’ ﬁ  les showed 
that most of these persons had hypoglycemia or hyperpar-
asitemia, and none were in septic shock. Moreover, these 
patients recovered rapidly after treatment, and all but 1 
were recruited during the high malaria transmission sea-
son, which support the argument that these persons had 
true cases of severe malaria.
The increased risk for uncomplicated malaria in HIV-
1–infected patients with a low CD4 count is consistent with 
information in several cohort studies (1). Although the ex-
tremely high proportion of a low CD4 count in patients 
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 5, May 2009  753 
Table 3. HIV-1 infection and HIV-1–related immunosuppression as risk factors for nonsevere and severe malaria, case–control study, 
Luanshya, Zambia* 
Participant characteristics  No. (%)  OR (95% CI)  p value  OR (95% CI)  p value 
HIV-1 infected† 
  Asymptomatic controls  13/29 (45)  1 –
  Controls with uncomplicated malaria  15/29 (52)  1.3 (0.5–3.7)  0.59 1 –
  Case-patients (severe malaria)  27/29 (93)  16.6 (2.5–111.8)  0.0005 12.6 (2.0–78.8)  0.0005
CD4 cell count <350/μL‡ 
  Asymptomatic controls  1/12 (8)  1 –
  Controls with uncomplicated malaria  11/14 (79)  7. 67 (1.78–33.01)  0.001 1 –
  Case-patients (severe malaria)  19/23 (83)  23.00 (3.35–158.00)  <0.0001 3.00 (0.83–10.83)  0.08
*OR, odds ratio; CI, confidence interval. 
†p value obtained by using matched-pairs signed-ranks test. 
‡CD4 count not measured in 4 HIV-1–infected case-patients, 1 control with uncomplicated malaria, and 1 asymptomatic control because of technical 
constraints. p value obtained by using Wilcoxon signed-ranks test and Wilcoxon rank-sum test. RESEARCH
in our study might have been confounded by a temporary 
malaria-induced reallocation of speciﬁ  c T cells; 70% had 
a CD4 count <350/μL 1 month after successful treatment. 
Therefore, immunosuppression is likely an additional risk, 
but absolute CD4 count cannot be interpreted during a se-
vere malaria episode.
Almost half of malaria cases throughout the world oc-
cur in areas where the disease is holoendemic (22). HIV-1 
program managers working in areas where both diseases are 
prevalent should be aware that HIV-1 infection—and cer-
tainly HIV-1–related immunosuppression—are important 
risk factors for severe malaria. Early detection of HIV-1 
infection is extremely important because comprehensive 
measures to prevent malaria and chemoprophylaxis with 
cotrimoxazole could be promptly implemented to protect 
against uncomplicated and severe malaria, a disease with 
a high fatality rate (23). Clinicians in such settings also 
should be aware of the strong association between severe 
malaria and HIV-1 so they can assess patients for other un-
derlying diseases and offer the opportunity for voluntary 
counseling and testing for HIV-1 when patients have re-
covered from malaria.
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1. Which of the following best explains the large scale 
of the HIV-1–malaria interaction that has emerged in 
the last decade?
A.   Longer survival of patients infected with HIV 
B.   Effects of increased antiretroviral drug use
C.   Poor immune function and higher susceptibility
D.   Poor control of malaria worldwide
2. A 28-year-old Zambian patient presents with a fever 
of 38.5°C, Plasmodium falciparum on thick smear with 
120 parasites per 200 white blood cells, and jaundice. 
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diagnosis?
A.   Uncomplicated malaria
B.   Moderately severe malaria
C.   Severe malaria
D.   HIV and malaria
3. The study noted the importance of fever as an 
indicator of severe malaria in patients infected with 
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commonly encountered in addition to fever?
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association between HIV-1 infection and risk for 
severe malaria in the population studied?
A.   HIV-1 infection is a risk factor for uncomplicated and 
severe malaria
B.   Risk for severe malaria is only increased in patients 
with HIV-1 with a CD4 count <250 cells/μL
C.   HIV-1 infection increases the risk for severe malaria
D.   Risk for severe malaria is increased only in patients 
with AIDS
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